Related Experiment Video
Updated: Jul 15, 2026

07:54
Isolation of Neonatal Extrahepatic Cholangiocytes
Published on: June 5, 2014
Growth evaluation in infants with neonatal cholestasis
Camila Carbone Prado1, Roberto José Negrão Nogueira, Antônio de Azevedo Barros-Filho
1Department of Pediatrics, State University of Campinas, SP, Brazil.
Arquivos De Gastroenterologia
|April 5, 2007
Summary
Infants with neonatal cholestasis show significant growth deficits, particularly those with extrahepatic cholestasis. Early nutritional and growth monitoring is crucial for these infants.
Area of Science:
- Pediatric Gastroenterology
- Neonatal Medicine
- Growth and Development
Background:
- Chronic childhood liver diseases frequently lead to undernutrition and growth failure.
- Growth parameters in infants diagnosed with neonatal cholestasis are not well-documented.
Purpose of the Study:
- To assess the nutritional status and growth patterns in infants experiencing intrahepatic cholestasis and extrahepatic cholestasis.
Main Methods:
- A retrospective review of 144 infants with neonatal cholestasis from 1980-2003.
- Patients were categorized into intrahepatic (Group 1) and extrahepatic (Group 2) cholestasis groups.
- Weight-by-age and height-by-age Z-scores were calculated at four distinct growth stages within the first year of life.
Main Results:
- Both groups exhibited weight-by-age Z-score declines, with Group 2 showing a significant deficit from the second stage onwards.
- Height-by-age Z-scores also decreased in both groups, with Group 2 experiencing a more pronounced deficit from the third stage.
- Significant differences in both weight and height Z-scores between Group 1 and Group 2 emerged by the third and fourth growth stages.
Conclusions:
- Weight and height deficits become statistically significant from the third measurement onwards, with extrahepatic cholestasis presenting the most substantial growth impairment.
- Evidence suggests the onset of weight and height deficits in the extrahepatic group occurs between the first and second evaluation stages.
- These findings underscore the critical need for early nutritional and growth monitoring in infants with neonatal cholestasis, especially those with extrahepatic forms.
Related Concept Videos
Pharmacokinetics in Pediatric Patients: Drug Metabolism
In pediatric care, understanding the nuances of hepatic drug metabolism is crucial, as it significantly differs from that of adults. This divergence is primarily due to the developmental stage of drug-metabolizing enzymes, which affects how medications are processed in the body. In neonates, for instance, the activity of Phase I enzymes—critical for the initial breakdown of drugs—is markedly reduced, functioning at just 20–40% of the levels seen in adults. This reduction poses a challenge in...
Pharmacokinetics in Pediatric Patients: Overview and Drug Absorption
Understanding the physiological differences in the pediatric population is crucial for effective pharmacotherapy. Neonates, infants, and children exhibit significant variations in gastric pH, gastric emptying time, intestinal transit time, and biliary function. These variations profoundly affect oral drug absorption, necessitating a nuanced approach to pediatric dosing.Neonates present with a unique physiological profile, having a gastric pH greater than 4 and faster and more irregular gastric...
Effect of Hepatic Disease on Pharmacokinetics: Pathophysiologic Assessment and Liver Function Test
In clinical practice, the direct measurement of hepatic blood flow to evaluate liver function presents significant challenges due to the intricate and specialized nature of the necessary techniques. Consequently, healthcare professionals often rely on empirical estimates derived from thorough patient examinations and liver function tests to gauge liver health. Among the tools at their disposal, the Child–Pugh and MELD scoring systems stand out for their ability to categorize and assess the...